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Abstract
A major obstacle to the management of malignant glioma is the inability to effectively deliver
therapeutic agent to the tumor. In this study, we describe a polymeric nanoparticle vector that not
only delivers viable therapeutic, but can also be tracked in vivo using MRI. Nanoparticles,
produced by a non-emulsion technique, were fabricated to carry iron oxide within the shell and the
chemotherapeutic agent, temozolomide (TMZ), as the payload. Nanoparticle properties were
characterized and subsequently their endocytosis-mediated uptake by glioma cells demonstrated.
Convection enhanced delivery (CED) can disperse nanoparticles through the rodent brain and their
distribution is accurately visualized by MRI. Infusion of nanoparticles does not result in
observable animal toxicity relative to control. CED of TMZ bearing nanoparticles prolongs the
survival of animals with intracranial xenografts compared to control. In conclusion, the described
nanoparticle vector represents a unique multifunctional platform that can be used for image-
guided treatment of malignant glioma.
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INTRODUCTION
There are over 22,000 new cases of primary malignant brain tumors diagnosed in the United
States each year.1 Despite standard multimodal treatment, median survival remains about
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one year and local tumor recurrence is virtually universal.2, 3 The addition of chemotherapy
to surgery and ionizing radiation (IR) improves patient survival,4 suggesting that better
therapeutic delivery can make a significant impact to overall patient prognosis. To improve
intracranial delivery, chemotherapeutic concentrations may be increased or the blood brain
barrier (BBB) temporarily opened. While such techniques increase the killing of tumor cells,
they also result in an increase in normal tissue toxicity. Direct intratumoral implantation of
drug (e.g. using impregnated polymers) can bypass the BBB, but agent distribution is
limited by its ability to diffuse through the tissue. Convection enhanced delivery (CED) is a
direct delivery method that uses a hydrostatic pressure gradient to distribute macromolecules
through the brain tissue via catheters implanted during surgery.5, 6
CED can significantly increase the volume of distribution (Vd) of infused macromolecules.
However, several studies, including a recent clinical trial,7 highlight the unpredictable nature
of agent distribution by CED.8 Loss of infusate into the ventricles and subarachnoid space or
the anisotropic tissue surrounding a tumor all contribute to the random nature of agent
dispersal.9, 10 This unpredictable pattern is seen despite optimal catheter placement. In an
attempt to overcome the limitation of random distribution, real-time or post-infusion
imaging can be used. Such an approach enables mid-procedure adjustments, or additional
treatments, to be made to target areas not initially covered. This treatment paradigm,
referred to as adaptive image guidance, is used extensively with radiation therapy of non-
central nervous system tumors.11
The development of new therapies for the management of malignant glioma has accentuated
the need for a vector system to effectively deliver these agents. A model vector is
biocompatible, non-toxic and stable in the tumor microenvironment. The ability to be
imaged is an additional attribute that has become more important as the first generation of
vectors has been tested clinically. Vector systems are generally divided into two groups:
viral and non-viral. Although viral vectors have received the most attention, they suffer from
significant drawbacks, such as their potential toxicity, difficulty with large-scale production
and inability to incorporate MRI contrast agents.12 Among non-viral vectors, liposomes
have had some clinical use in the delivery of chemotherapeutics.13 Nevertheless, no system
has stood out as being significantly better than another in the management of malignant
glioma.
Polymeric nanoparticles (NPs) are compelling for use as multi-dimensional vehicles because
not only can they deliver a therapeutic payload, but they can also be fabricated to
incorporate an MRI contrast agent for real-time imaging. To date, convection of
nanoparticles has not been well studied, and the stringent requirements necessary for NP
dispersion by CED,14, 15 mean that each NP system needs to be systematically tested and
modified in order to optimize their distribution in the brain. In this study, we report the
production of a polymeric NP vector containing iron oxide and loaded with the anti-glioma
agent, temozolomide (TMZ). These NPs, fabricated specifically for CED, can be convected
through the rodent brain and tracked in vivo by standard MR imaging. Furthermore, TMZ-
encapsulating NPs are shown to effectively reduce the growth of glioma xenografts and
extend survival of tumor bearing animals.
METHODS
Animals and cells
Six- to 7-week-old male Lewis rats or male athymic nude mice (Harlan Laboratories,
Indianapolis, IN) were used as described below. Surgery was performed in accordance with
the guidelines of the Institutional Animal Care and Use Committee of the University of
Chicago to provide humane care of these animals. The human glioblastoma cell line, U87
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MG, was acquired from the American Type Culture Collection (ATCC) and cultured as
previously described.16
Polymeric magnetite-bearing NP (PMNP) fabrication and characterization
PMNPs were produced using a proprietary electrohydrodynamic technology (Bio-Target
Inc. and LNK Chemsolutions LLC, USA). Briefly, for all NP formulations, organic
solutions containing all the necessary components were processed using this technology
resulting in a dry collection of the specified nanoparticles. The collected material was then
harvested in an aqueous buffer solution to obtain a stable suspension. The NP formulations
used include: 1) Blank PMNPs (particles containing only polymers and magnetite); 2)
Fluorescent PMNPs (same composition as Blank PMNPs, with either rhodamine or
fluorescein); and 3) TMZ-containing PMNPs (same components as Blank PMNPs, plus
fluorescein and TMZ). PMNPs were suspended in a 2:2:1 solution of 1% (w/v) BSA, pH 7.4
PBS and sterile water, respectively. For payload release, PMNPs were suspended in 0.25%
Tween-20 in pH 7.4 PBS solution, to avoid BSA interference in the UV-Vis analysis.
Centrifugation was performed at 9,500 g for 4 min to isolate sub-100 nm particles from the
crude fraction. For dynamic light scattering (DLS) analysis, PMNPs were diluted 1:20 in
PBS and a Zetasizer Nano ZS (Malvern, Worcestershire, UK) was used. For Transmission
electron microscopy (TEM) studies, a TEM JEOL model 1220 at 120kV was used. Magnetic
susceptibility experiments were carried out on a Superconducting Quantum Interference
Device (SQUID) with dry pellets of 1/8×, 1/2x, 1×, and 2× PMNPs (where x= a magnetite
concentration of 13.2 μg/μl). Magnetic fields ranging from −5 to +5T were used, as this
range includes field strengths found in common human and animal MRI scanners.
For examination of in vitro release kinetics, 100 mg of as-collected nanoparticles were
suspended in 10 ml of 0.25% PBS-Tween Buffer (pH=7.4). Since TMZ is only stable at
acidic pH in aqueous solution, the history of TMZ released from the particles would be
masked if the TMZ present in solution is included in the quantification. To solve this
problem, only TMZ protected inside the particles is quantified after separating the particles
from the liquid in the suspension and then chemically disrupting the polymers by adding 100
μl of HCl 0.1 N. Once the polymer in the nanoparticles was completely disrupted, the
supernatant was separated and TMZ quantified by UV-Vis spectroscopy (HP 8452 A Diode
Array Spectrophotometer) following the absorbance at 330 nm wavelength that corresponds
to the aromatic ring carbonyl group of TMZ n-γ electronic transition.17 At t=0, the amount
of TMZ quantified is the total initial TMZ content in the particles. At any other time in
suspension, an aliquot can be isolated, particles separated and disrupted, and its TMZ
content quantified as above. The TMZ released from the particles into the solution up to that
time, regardless of decomposition in aqueous solution, is determined by subtracting the
measured amount in the particles at the given time from the total initial amount of TMZ.
Release studies were performed at 4°C, 22°C and 37°C and all measurements performed in
duplicate.
PMNP uptake
For uptake quantification studies, U87 cells were pretreated with either 30 nM
chlorpromazine (Sellekchem Inc, Houston, TX) or 450 mM sucrose for 30 minutes prior to
nanoparticle administration. The indicated volume of PMNPs was added to cells in 2.5 ml of
media and kept in the same media containing the inhibitors for two hours prior to analysis
using a FACSort instrument (Becton Dickinson Immunocytometry Systems, San Jose, CA).
For fluorescence microscopy studies, U87 cells were plated overnight and then incubated
with either 1 μl of rhodamine-tagged PMNPs or rhodamine in media for two hours. Cells
were then rinsed twice and fixed for 10 min with formalin. Following two more rinses, each
well was coverslipped using ProLong Gold with DAPI nuclear stain (Invitrogen, Carlsbad,
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CA). Cells were then visualized with Olympus DSU Spinning Disk Confocal microscope
using an Evolve back-thinned CCD camera.
CED and PMNP distribution
CED was performed using a step-design catheter similar to one previously described.18
Briefly, the catheter was made of fused silica tubing (167 μm OD and 100 μm ID) attached
to a 26 gauge needle connected via PEEK tubing to a 250 μL Hamilton syringe (Reno, NV)
and powered by a BASi syringe pump (West Lafayette, IN). For distribution experiments,
rats were placed in a Kopf stereotactic frame to target the right striatum (1.0 mm AP, 3.0
mm L, and 6.0 mm Ventral to bregma). The catheter was slowly lowered and after 5
minutes, 25 μl of NPs infused at a rate of 0.5 μL/min. The catheter was then slowly retracted
and animals recovered. Bolus injections were performed using the same catheter system at
an infusion rate of 25 μL/min.
In vivo MRI
PMNPs or PNPs were infused via either CED or bolus and animals placed in the MRI
scanner within 1 hour of infusion termination. T2-weighted MR images were acquired using
a 9.4T GE MRI and a low pass birdcage RF coil. T2-weighted fast spin echo MR images
were acquired with a 256× 256 matrix, TR/TE 300/4.1 to 701/2.7 ms, echo time of 64 ms,
and 0.5 mm slices with no gap. Animals were sacrificed immediately following MRI
acquisition and images analyzed with OsiriX (Pixmeo, Geneva, Switzerland).
Histology
Rats were sacrificed immediately after infusion, or in some cases after MRI, and the brains
removed, fixed in OCT (Sakura Finetek USA Inc., Torrance, California) and sectioned at 20
μm with a cryostat. For fluorescently-tagged NPs, sections were examined at low power
with a FITC filter, and images analyzed using ImageJ (NIH). For analysis of general brain
histology and for determination of iron oxide distribution, formalin fixed brains were
sectioned and then stained with either hematoxylin and eosin or Prussian blue dye,
respectively.
Calculation of Vd/Vi
To calculate and compare the volume of distribution to volume of infusion (Vd/Vi) ratio
between bolus and CED infusions, serial images displaying the infusion site were identified
using ImageJ (NIH) and the region of either hypointensity (MRI) or fluorescence
(fluorescence imaging) selected. The cross-sectional area of signal for each section was
calculated using the known section thickness (defined as the distance between consecutive
cryostat sections), and summed across serial sections to obtain Vd. The Vd was then divided
by the volume of infusate administered (Vi). Backflow, dorsal to the corpus callosum, was
excluded from the volume measurements in both CED and bolus infusion.
In vivo glioma studies
Hind limb experiments—For hind limb experiments, 5×106 U87 cells in a 100 μL
suspension were inoculated into the right hind limb muscle of nude mice and tumor size
measured daily with calipers. When tumors reached an average size of 200 mm3, animals
were randomized into four groups and treatment started (day 0). For all treatments, the
respective PMNP formulations were injected intratumorally on day 0, 3 and 5. Treatment
groups included: i) untreated control (UTC), ii) blank-NPs (no TMZ), iii) TMZ-loaded NPs
(TMZ equivalent concentration was 5 mg/kg/dose), and iv) the supernatant acquired after
filtering TMZ-loaded PMNPs through a 10 nm filter. Fractional tumor volume, relative to
day 0 for each individual animal, was plotted every 2-3 days.
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Intracranial experiments—5×105 U87 cells were inoculated into the right striatum as
previously described.16 On day 4 and 7 after tumor grafting, animals were treated with 10 μl
of the indicated PMNPs infused by CED intracranially to the same coordinates as the tumor.
Mice were monitored daily and sacrificed when they displayed signs of terminal disease.
Statistical analysis
Results are expressed as mean ± SD. Statistical significance was taken as P < 0.05, using 2-
tailed Student’s t-test. Kaplan-Meier survival curves were plotted for the intracranial
experiment and analyzed by the log-rank method.
RESULTS
Development and characterization of optimal PMNPs for CED through the brain
In designing NPs for use against malignant glioma, a polymer system composed of a
mixture of functionalized polyethylene glycol (PEG), polylactide (PLA), and
polycaprolactone (PCL) was used. Such a polymer enables formation of <100 nm diameter
NPs with a negative surface charge, two properties that allow for robust convection through
the extracellular space of brain parenchyma.14 Additionally, PEG-PLA-PCL was chosen as
it can incorporate a variety of compounds within the polymer on forming NPs.
Superparamagnetic iron oxide (magnetite) was incorporated into the NP shell to produce
PMNPs (Figure 1A). At each stage in NP development, the ratio of the components was
systematically adjusted to optimize encapsulation, drug delivery and imaging. Both
Dynamic light scattering (DLS) studies (Figure 1B) and transmission electron microscopy
(TEM; Figure 1C) reveal that NPs have a diameter of <100 nm, and a slightly negative
surface charge (zeta, ζ, potential = −7.75 mV; data not shown). Magnetic susceptibility
measurements reveal that an increase in iron oxide concentration results in an increase in
magnetic susceptibility in fields up to 5 Tesla (Figure 1D), confirming the
superparamagnetic property of the NPs. PMNPs with 11 % iron oxide content were found to
offer the best balance between polymer content and magnetic susceptibility. Finally, TMZ
release was determined using UV-Vis spectroscopy. At 37°C, complete release of payload
(TMZ) is achieved after approximately 20 hours, while at lower temperatures PMNPs are
more stable with a slower release profile (Figure 1E). These data indicate that PMNPs have
characteristics that are compatible with CED and, while stable when refrigerated, PMNPs
release their payload more quickly at physiological temperature.
CED efficiently distributes PMNPs in the rat brain
A rat model was used to examine CED through the brain. Using a step design catheter
system,18 fluorescein-tagged PMNPs were infused into the striatum of Lewis rats either via
CED or bolus injection (Figure 2A). Fluorescence microscopy of histological specimens
reveals that CED results in significantly higher Vd relative to Vi when compared to the ratio
achieved with bolus injection (P < 0.05, Figure 2B). Importantly, animals subjected to
PMNP infusion do not show any systemic signs of distress or trauma compared to controls.
Next, PMNP dispersion was examined in vivo using MRI (Figure 2C). As with fluorescence
imaging, MRI studies show that delivery by CED results in a significant increase in PMNP
distribution relative to bolus infusion (Figure 2D, P < 0.05). Serial T2-weighted images of a
representative MR scan demonstrate the presence of hypointense signal centered on the
CED infusion site (Figure 2C, white arrows). Bolus injection fails to distribute PMNPs
ventral to the catheter tip, resulting instead in PMNP backflow along the catheter tract
(Figure 2C, black arrows). The Vd/Vi values calculated on MRI are similar to their
respective values as determined by fluorescence microscopy (Figure 2D). Although the
hypointense signal seen following PMNP infusion is likely due to the iron oxide, we
Bernal et al. Page 5
Nanomedicine. Author manuscript; available in PMC 2014 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
confirmed this observation by infusing NPs that do not contain iron oxide. While iron oxide
containing PMNPs produce a hypointense MR signal following CED, identical NPs that
have no iron oxide (PNPs) do not (data not shown). These findings indicate that CED can
effectively distribute PMNPs and that it is specifically the iron oxide in the PMNPs, and not
a different factor associated with the infusion, that is visualized by MRI.
Histological examination of rat brains was also performed to analyze both the pathology and
distribution of bolus compared to CED administration. Focal, procedure-related hemorrhage,
demonstrated by the presence of red blood cells, is observed at the site of catheter insertion
following both bolus injection (Figures 3A and B) and CED infusion (Figures 3C and D).
While CED results in some local edema, as demonstrated by the mild increase in the
extracellular space size in the region of infusion (Figures 3C and D), no gross parenchymal
changes are seen following infusion. This observation suggests that convection of PMNPs
does not grossly damage the surrounding brain tissue. In addition, PMNP distribution was
examined by staining for iron oxide using Prussian blue dye (Figure 3E). CED results in iron
oxide distribution distant from the injection site, a finding consistent with the results
obtained on MRI and fluorescence imaging.
PMNPs are taken up by glioma cells and deliver effective TMZ
PMNP cellular uptake was initially quantified using FACS analysis of cells incubated with
fluorescently-tagged PMNPs. A concentration-dependent increase in nanoparticle uptake is
noted within 2 hours of exposure of cells to PMNPs with close to 100 % of cells being
positive when 0.5 μl of PMNP are used (Figure 4A, left). In addition, fluorescence imaging
demonstrates PMNP uptake specifically in the cytoplasm (Figure 4A, right). Next, to
examine the role of endocytosis in PMNP uptake, chlorpromazine (CPZ), a clathirin-
mediated endocytosis inhibitor,19 and hypertonic sucrose solution, a non-selective
endocytosis inhibitor,20 were used. A significant decrease in fluorescence-positive cells is
seen following pre-treatment with either CPZ or hypertonic sucrose, especially at low
PMNP concentrations (Figure 4B), indicating that PMNP uptake is at least in part
endocytosis-mediated. The ability to deliver therapeutic agent was assessed by examining
clonogenic survival following exposure of cells to PMNPs loaded with TMZ. TMZ-PMNPs
decrease the surviving fraction of U87 cells in a concentration-dependent manner whereas
even a high concentration of blank PMNPs does not affect surviving fraction compared to
untreated cells (Figure 4C). To examine whether uptake of TMZ-loaded PMNPs is required
for this effect, clonogenic survival was examined in the presence of hypertonic sucrose.
Hypertonic sucrose has a small effect on clonal survival on its own and does not
significantly alter survival following treatment with blank PMNPs (Figure 4D). However,
sucrose completely reverses the decrease in colony formation induced by TMZ-PMNPs
(Figure 4D). Importantly, these results are not due to hypertonic sucrose altering the
integrity of PMNPs themselves as determined by examining PMNPs that were pre-incubated
in sucrose prior to use (data not shown). Together, these data suggest that PMNPs need to be
taken up by glioma cells and release their therapeutic payload intra-cellularly for the
cytotoxic effect.
To assess the anti-glioma effect of TMZ-PMNPs, two animal models of malignant glioma
were used. First, U87 glioma xenografts were established in the hind limb of athymic nude
mice and tumors treated with a single intra-tumoral injection of TMZ-PMNPs, blank
PMNPs, or the supernatant after filtering TMZ-PMNPs. Fractional tumor volume, relative to
day 0, was then compared to that of untreated controls (UTC). TMZ-PMNPs significantly
reduce tumor growth compared to untreated and those treated with blank PMNPs (P < 0.05
at day 20) (Figure 5A). Furthermore, no change in growth is seen following administration
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of the filtered supernatant suggesting that TMZ is contained within the PMNPs themselves
and not free in the solvent.
Given the critical importance of the local environment in the treatment of malignant glioma,
we next examined treatment efficacy using an intracranial glioma model. U87 xenografts
were established in the striatum of athymic nude mice and animal survival monitored
following CED of TMZ-PMNPs compared to controls. Administration of TMZ-PMNPs
significantly extends the survival of xenografted mice when compared to both untreated
animals and those treated with blank-PMNPs (P < 0.03, Figure 5B). These data indicate that
PMNPs can safely deliver effective concentrations of chemotherapeutic agent intracranially
and suggest that this system can be used to treat malignant glioma.
DISCUSSION
In the current work, we describe a polymeric nanoparticle vector specifically designed for
image-guided treatment of malignant glioma. Nanoparticles were fabricated using a
combination of FDA-approved polymers to produce a vector with optimal properties for
convection through the brain parenchyma.15, 21 Specifically, NPs with a diameter less than
100 nm and a negative surface charge were obtained. In addition, NPs were loaded with
superparamagnetic iron oxide for MR imaging. These PMNPs were designed to have a core/
shell structure that allows them to protect a specific payload in their center (Figure 1A).
Although the anti-glioma agent, TMZ, was used as the payload for this work, it is
anticipated that a broad range of therapeutics or toxins can be encapsulated and delivered. In
initial studies, we characterized the physical properties and payload release profile of
PMNPs. Subsequently, CED was employed to disperse PMNPs through rat brains and their
distribution pattern examined using MRI. In addition, the ability of PMNPs to be taken up
into cells and deliver viable TMZ was examined in cell culture experiments. Finally, after
having determined that this vector is safe for use in vivo, studies were performed in animal
glioma models to demonstrate the efficacy of PMNP as a vector for delivery of
chemotherapeutic to the brain.
The BBB represents one of the most important obstacles to the effective treatment of
malignant glioma. One technique used to bypass this barrier and deliver adequate levels of
therapeutic to glioma cells involves direct intra-parenchymal injection using CED.6 We
demonstrate that PMNPs can be distributed in the brain parenchyma by CED. Although this
technique enables a larger Vd than using simple bolus, it is notable that the Vd/Vi of PMNP
dispersion is less than 1 (Figure 2). While this distribution ratio is adequate for treatment of
an animal model of malignant glioma, some concern is raised for the potential translation of
this technique to clinical tumors where tissue characteristics surrounding gliomas will
further restrict the ability to adequately cover the tumor. Specifically, the inhomogeneity and
anisotropy of glioma-infiltrated brain can yield unpredictable distribution geometry
following CED.22 Indeed, the disappointing results of recent clinical trials using CED can, at
least in part, be attributed to insufficient tumor coverage following convection.23 While
infusing greater volumes of PMNPs, for longer periods of time, may improve the overall
tumor coverage, it is conceivable that PMNP infusion may be best used to target small
regions of residual tumor that remain following surgical debulking.
Given the difficulty with predicting distribution pattern following CED, a significant
advantage of PMNPs is the ability to visualize them with standard MRI. As CED is a blind
process, real-time and post-operative imaging is essential to confirm that the delivered
therapeutic adequately covers the intended target region. In the event of insufficient
coverage, the infusion can be redirected or additional infusions performed to enable
maximal target coverage. PMNP distribution pattern was demonstrated with MRI and
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verified histologically both by fluorescence imaging and iron oxide staining. While it is
clear that iron oxide is a useful contrast agent,24 consideration must also be given to the
potential toxicity associated with accumulation of this molecule in the brain. In this regard,
it has been reported that uncoated iron oxide NPs can induce reactive oxygen species
production, inflammation and DNA damage.25 However, coating iron oxide with polymers
such as PEG has been shown to render PMNPs biocompatible.26 In the long term, iron oxide
crystals are in part metabolized, leading to increased hepatic and splenic ferritin storage, and
in part incorporated into red blood cells.27 While it is reported that iron oxide remains in
brain tissue even 3 months after injection, histological data shows no gross pathological
findings associated with this accumulation.28 Moreover, our results show that after 3 weeks,
the MRI signal is reduced to less than 25 % of the original (data not shown) and that PMNP
infusion is well tolerated with minimal toxicity.
Despite the efficacy of using PMNPs to deliver TMZ in vivo, that the actual drug delivery
efficiency is quite low. This finding may hinder the potential clinical use of PMNPs. To
improve overall delivery, targeting moieties such as antibodies or ligands can be
incorporated onto the PMNP surface to increase delivery efficiency as previously reported.24
Also, increasing the drug concentration within the PMNPs may improve the total amount of
agent delivered. Ultimately however, the potential of this system for clinical use will require
further examination in higher order animals that have spontaneous tumors such as found in a
canine model.29 It is also possible that PMNPs may be better suited for delivery of other
types of therapeutic agents. In this regard, the ability of PMNPs to specifically deliver their
payload to the cellular cytoplasm suggests that they may be ideal for delivery of si-RNA that
mediates its effect in the cytoplasm.
In conclusion, we present a novel nanoparticle vector that represents a versatile platform that
can be used to overcome many delivery-related obstacles associated with treatment of
malignant glioma. Importantly, successful intracranial delivery raises the possibility of using
such a system not only for treating tumors but also for the management of a broad range of
central nervous system diseases.
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Figure 1. Nanoparticle Characterization
(A) Anatomy of PMNPs fabricated to incorporate superparamagnetic iron oxide (magnetite)
into a fluorescently-tagged shell. The payload is protected within the core. (B) Dynamic
light scattering (DLS) analysis of PMNPs. (C) Transmission electron microscopy of PMNPs
with scale bar set at 200 nm. (D) Magnetic susceptibility of PMNPs with increasing
concentrations of magnetite is plotted (1× = 5.5% magnetite). The superparamagnetic
behavior is shown in that no hysteresis is apparent as the applied magnetic field is cycled (y
axis: applied field and x axis: sample magnetization). (E) Release dynamics of TMZ as
assessed by spectrophotometry at the indicated temperature.
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Figure 2. CED increases intracranial distribution of PMNPs
(A) Sequential images of a representative rat brain following infusion of 25 μl PMNPs by
CED (white arrows) or bolus injection (black arrows). Slices represent a total of 900 μm in
the AP-dimension. (B) Graph of Vd/Vi following infusion of 25 μl of fluorescent PMNPs.
Data shows mean value +/− SD. (n = 4 animals per group). * P < 0.05. (C) Sequential T2
weighted images following CED (white arrows, right) or bolus infusion (black arrows, left)
of 25 μl PMNPs. Slices represent a total of 3.0 mm in the AP-dimension. (D) Vd/Vi
following CED or bolus injection as assessed by MRI following infusion of 25 μl PMNPs.
(n = 4 animals per group). * P < 0.05.
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Figure 3. CED of PMNPs does not cause excessive tissue damage
(A-D) Hematoxylin and Eosin stained sections of brain tissue following PMNP infusion. (A
and B) Bolus injection of PMNP (magnified insert is shown in B). (C and D) CED infusion
(magnified insert is shown in D). (E) Prussian blue staining following PMNP infusion by
CED. Boxed areas distant from the infusion site are magnified on the right (inserts i and ii).
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Figure 4. PMNPs are taken up by glioma cells and deliver viable TMZ
(A) Uptake of PMNPs by U87 cells as demonstrated by FACS analysis (left) and confocal
imaging (right) following exposure to rhodamine-tagged PMNPs (NP-Rhod) or rhodamine
dye alone (UTC) for 2 hours. Rhodamine (TRITC) and nuclei (DAPI) were imaged as
shown. (B) FACS analysis of PMNP uptake in the presence of the endocytosis inhibitors,
chlorpromazine (30 μM) or hypertonic sucrose (450 mM). (C) Clonogenic assay of U87
cells following treatment with increasing amounts of TMZ loaded PMNPs (TMZ NP) or
blank PMNPs. (D) Clonogenic assay of U87 cells, in the presence of 450 mM sucrose or
regular media, following treatment with TMZ (50 μM), blank PMNPs, or TMZ-carrying
PMNPs (carrying 50 μM TMZ). Clonogenic data show mean surviving fraction, normalized
to untreated, of triplicate samples +/− SD. * P < 0.05 and ** P < 0.01 relative to untreated
control.
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Figure 5. TMZ-PMNPs demonstrate anti-glioma efficacy
(A) U87 hindlimb xenografts were allowed to grow to an average of 200 mm3 and animals
randomized into the groups indicated (n = 5 per group). Graph shows ratio of the tumor
volume on any given day (V) relative to the volume of the same tumor on the day treatment
was initiated (V0) +/− SD, following treatment with the indicated PMNP. * P < 0.05, TMZ
loaded PMNPs (TMZ NP) relative to untreated (UTC). (B) Kaplan-Meier curve of mice
bearing intracranial U87 xenografts either untreated or treated with TMZ-PMNPs or Blank-
PMNPs. (n = 5 animals per treatment group). P < 0.03, TMZ-PMNPs versus Blank-PMNPs.
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